As an example, tomuzotuximab, an afucosylated EGFR-directed mAb, failed to demonstrate improved efficacy compared to cetuximab in the first-line treatment of recurrent or metastatic HNSCC (RESGEX study) (147). Here, EGFR is linked to head and neck squamous cell carcinoma.